This trial is evaluating whether Bulevirtide will improve 2 primary outcomes and 15 secondary outcomes in patients with Hepatitis D, Chronic. Measurement will happen over the course of Posttreatment Week 24.
This trial requires 150 total participants across 6 different treatment groups
This trial involves 6 different treatments. Bulevirtide is the primary treatment being studied. Participants will be divided into 6 treatment groups. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"In the United States, hepatitis D is an infection that is primarily spread through blood transfusions. With proper treatment, infection is highly unlikely. In individuals at high risk of hepatitis D, however, infection should be considered." - Anonymous Online Contributor
"The signs of hepatitis d are not specific for CHD as they are with AIH. These same signs of CHD are also present in those with acute viral hepatitis and alcoholic hepatitis. CHD is differentiated from AIH by the absence of circulating S-IgG with reactivity to HEV antigens, and the presence of anti-dsDNA in CHD. This diagnostic feature may be of utility in guiding treatment." - Anonymous Online Contributor
"Alcohol consumption is the major cause of hepatitis D. Exposure to non-immune blood products is a minor cause of hepatitis D. There is a relationship between hepatitis D and mental health. The effectivity of immunization against hepatitis D depends on the vaccinating dose. The hepatitis D virus was discovered in 1979 from the blood of an African with chronic liver disease." - Anonymous Online Contributor
"Overall, we found that hepatitis A, B, and C were commonly diagnosed; however, only one-third of the individuals with hepatitis had chronic HBV, and one-quarter had chronic HCV. Although men were significantly more likely to have hepatitis A than women, this risk was outweighed by a greater number of women with chronic HCV. In the US pediatric population, only hepatitis B was commonly diagnosed, and the majority of children with chronic HBV had HCV." - Anonymous Online Contributor
"Hepatitis D infection is a chronic infectious disease caused by an icosahedral DNA virus, which is a member of the genus "Deltaretrovirus" of the family "Retroviridae." Hepatitis D has been known to be a major cause of liver cancer (HCC) in some of developing countries of Asia because HCCs occur in more than 82% of people infected with the virus." - Anonymous Online Contributor
"Most patients received some treatment of hepatitis D/V, but more than two thirds had no antiviral therapy within the previous 12 months. Findings from a recent study suggest that most individuals with hepatitis D receive no antiviral therapy after diagnosis." - Anonymous Online Contributor
"Clinical research on hepatitis D, chronic has progressed significantly. In the past few years, various studies have demonstrated the potential in the treatment option for hepatitis D, chronic. Some clinicians have initiated and continued treatment of hepatitis D, chronic. However, there is a lack of awareness in clinical society to the importance of patient's participation in clinical trials of chronic hepatitis and treatment of hepatitis D, chronic. On one hand, we should not underestimate the value of clinical trials in chronic hepatitis and hepatitis D, chronic. On the other hand, patients should not be ignored because they have the last word in healthcare and are in the position of power." - Anonymous Online Contributor
"This presentation provides recent research on hepatitis D and chronic hepatitis and the relevance of D viral infections to hepatitis D-associated liver disease and HCC. This presentation addresses key questions of how best to tailor medical interventions for hepatitis D and chronic hepatitis treatment." - Anonymous Online Contributor
"Findings from a recent study of these two studies do not support the current use of bulevirtide to treat the full range of CID that is currently treated with IFN-α alone in addition to the aforementioned immunosuppressive agents." - Anonymous Online Contributor
"To date, no approved vaccine exists to protect patients with hepatitis D from exposure to this potentially harmful virus. Liver transplants do help some patients; however, they are not always definitive and not always an option. Liver transplantation is the last resort for only the most seriously ill patients. At current time, there is no approved effective monoclonal antibody therapy to treat hepatitis D. Although hepatitis D can be treated with antiviral agents from a broad number of agents, including interferon alpha, ribavirin, and peginterferon alfa as well as hepatitis D antigen immunoassays, the treatment does not eradicate viral infection." - Anonymous Online Contributor
"Since many factors can cause hepatitis d, chronic, it is difficult to pinpoint the primary cause. It is likely that hepatitis d is caused by numerous factors. It is important, however, to distinguish the hepatitis d, chronic, in the early stages of hepatitis d. Chronic may be the cause of the early stages of hepatitis d, but may be overshadowed by other causes in the late stages of the disease progress." - Anonymous Online Contributor
"BuLev did not reduce fatigue, improve quality of life, or reduce the need for rest in patients with chronic hepatitis B (CHB). Patients can be confidently encouraged to continue therapy when treatment fails, while the rationale of prescribing the drug is questioned. Further research on treatment for fatigue and quality of life in CHB is warranted." - Anonymous Online Contributor